Axe Compute Inc. Q3 FY2022 earnings call

• Raymond Vennare introduces himself, emphasizing his background in commercializing biotech and commitment to the company. He highlights the biobank value exceeding $400M, integration of PeDAL technology with biobank as a differentiator, and the GMP facility. He mentions refreshing the brand by consolidating segments into service lines within the CLIA laboratory.
• Pamela Bush discusses the value of the PeDAL platform in oncology drug development, enabling preclinical testing of drug compounds against human tumor samples to inform clinical trials. She talks about working on lead contracts and relationships with top biopharma companies.
• Bob Myers provides financial updates, mentioning a strong cash position with $25M in account and $29M equity, no debt, and the biobank value not on the balance sheet. He addresses goodwill write-down related to zPREDICTA and progress with GMP lab and contracts.

No detailed segment financial performance with absolute terms and revenue contribution % provided as the transcript focuses on company overview and strategic aspects rather than breaking down product segments by financials.

• Aim to avoid reverse split by demonstrating stock value through deals and progress.
• Insuring the biobank asset for its value within the next couple of weeks.
• Progressing with GMP lab and ongoing negotiations with customers, working to generate contracts.

• Market volatility impacting stock price and goodwill impairment.
• Long sales cycle in the biopharmaceutical industry.
• Regulatory challenges inherent in the highly regulated biopharmaceutical sector.

Q: Michael Broadbent asked about the company's plan to get compliance and avoid reverse split, and if an offering after reverse split can be avoided.

A: Bob Myers responded that the company intends to avoid reverse split by showing stock value through deals, has a strong cash position with warrants exercisable between $0.80 and $1.25, and mentioned insuring the biobank asset.

Q: Robert Antonioni inquired about the value of zPREDICTA and its revenue realization.

A: Bob Myers discussed goodwill write-off due to stock decrease, and Pamela Bush talked about working on additional tumor type models and cross-selling services like PeDAL platform and formulation solutions within existing customer base.

Q: Robert Antonioni followed up on the GMP lab status and level of interest.

A: Raymond Vennare stated that the GMP lab is progressing, with Larry Lucas making connections at conferences, ongoing negotiations, and NDAs with companies indicating interest.